Trials / Active Not Recruiting
Active Not RecruitingNCT06132256
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 145 (actual)
- Sponsor
- Syndax Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axatilimab | Administered as intravenous (IV) infusion |
| OTHER | Placebo | Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient. |
Timeline
- Start date
- 2023-12-11
- Primary completion
- 2026-09-01
- Completion
- 2026-11-01
- First posted
- 2023-11-15
- Last updated
- 2026-03-27
Locations
78 sites across 13 countries: Australia, Belgium, Canada, Czechia, France, Germany, Italy, Poland, Romania, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06132256. Inclusion in this directory is not an endorsement.